Dem301

Phase 1

DDEM BioPharma, Inc.

Dem301 is one of 43 therapeutic programs targeting Metastatic Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Metastatic Colorectal CancerRecruiting

Metastatic Colorectal CancerPhase 1

Recruiting

Competition

Competitive Landscape

144 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Opdivo

Bristol-Myers Squibb

Phase 3

13 3

Braftovi

Pfizer

Phase 3

11 4

Yervoy

Bristol-Myers Squibb

Phase 3

7 5

Bayer Aspirin

Bayer

Phase 3

2 6

Folinic Acid

Roche

Phase 3

17 7

FOLFOX

AstraZeneca

Phase 3

14 8

Trifluridine/tipiracil

AbbVie

Phase 3

11 9

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

5 10

Mfolfox6

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 1Recruiting

Metastatic Colorectal Cancer

NCT07805369

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

A Phase 1, Open-Label, Two-Part (Dose Escalation and Expansion) Study of DEM301 in Participants With Select Advanced Solid Tumors

Recruiting·DDEM BioPharma, Inc.·Phase 1·NCT07805369·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dem301. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Dem301. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — DEM BioPharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: DDEM BioPharma, Inc.

Dem301

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News